Tag: interchangeable biosimilar
GENERAL Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market

Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]

CW Bureau · Aug 3, 2026
GENERAL Lupin Secures USFDA Approval For Ranibizumab Biosimilar Ranluspec

Global pharmaceutical major Lupin has received approval from the US Food and Drug Administration (FDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis, marking a significant milestone in the company’s expanding biosimilars portfolio. The approval makes Ranluspec the only interchangeable ranibizumab biosimilar in the United States available in both vial and pre-filled syringe (PFS) presentations. […]

CW Bureau · Jun 5, 2026